Anemia, Renal Dysfunction, and Their Interaction in Patients With Chronic Heart Failure

Academic Cardiology, University of Hull, Castle Hill Hospital, Cottingham, United Kingdom.
The American Journal of Cardiology (Impact Factor: 3.28). 08/2006; 98(3):391-8. DOI: 10.1016/j.amjcard.2006.01.107
Source: PubMed


Anemia and renal dysfunction (RD) are frequent complications seen in chronic heart failure (HF). However, the prevalence and interaction of these co-morbidities in a representative population of outpatients with chronic HF is poorly described. In this study, it was sought to determine the association between RD and anemia in patients with HF enrolled in a community-based HF program. Nine hundred fifty-five patients with HF due to left ventricular systolic dysfunction were investigated for the prevalence of anemia and its cause and followed for a median of 531 days. Anemia was defined as hemoglobin < 12.0 g/dl in women and < 13.0 g/dl in men. RD was defined as a calculated glomerular filtration rate of < 60 ml/min. The prevalence of anemia was 32%. Fifty-three percent of patients with and 27% of those without anemia had > or = 1 test suggesting hematinic deficiency. The prevalence of RD was 54%. Forty-one percent of patients with and 22% of patients without RD had anemia, with similar proportions associated with iron deficiency in the presence or absence of RD. Anemia and RD independently predicted a worse outcome, and this effect was additive. In conclusion, in outpatients with chronic HF, anemia and RD are common and co-exist but confer independent prognostic information. A deficiency of conventional hematinic factors may cause about 1/3 of anemia in this clinical setting.

1 Follower
10 Reads
  • Source
    • "When administered in combination with oral or intravenous iron, the erythropoiesis-stimulating agents were associated with an improvement of the severity of heart failure, characterized by decreased hospitalization; improvement of the functional class; 6-minute walking test showing a decrease in oxygen consumption during the test; reduction in BNP levels; increase in ejection fraction; and improvement of the quality of life45,46. There were also evidences of improvement of the renal function; reduction of diuretic dose, heart rate, and depression signs; improvement of sleep apnea; reduction of plasma volume; and improvement of the ventricular function and oxidative stress12,16,47,51. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anemia is a prevalent comorbidity and marker of a poorer prognosis in patients with heart failure (HF). Its clinical relevance, as well as its pathophysiology and the clinical management of these patients are important subjects in the specialized literature. In the present review, we describe the current concepts on the pathophysiology of anemia in HF, its diagnostic criteria, and the recommendations for iron supplementation. Also, we make a critical analysis of the major studies showing evidences on the benefits of this supplementation. The four main components of anemia are addressed: chronic disease, dilutional, "renal" and malabsorption. In patients with HF, the diagnostic criteria are the same as those used in the general population: serum ferritin levels lower than 30 mcg/L in patients without kidney diseases and lower than 100 mcg/L or serum ferritin levels between 100-299 mcg/L with transferring saturation lower than 20% in patients with chronic kidney diseases. Finally, the therapeutic possibilities for anemia in this specific patient population are discussed.
    Arquivos brasileiros de cardiologia 07/2013; 101(1):87-92. DOI:10.5935/abc.20130126 · 1.02 Impact Factor
  • Source
    • "Besides being a cause of anaemia in CHF, iron deficiency seems to be frequent in CHF and is associated with worse prognosis regardless of the presence of anaemia.6 The prevalence of iron deficiency in CHF varies widely, from 5% to 73%, depending on the population studied and the methods used to define iron deficiency.6,4,13,23,24 In a group of 546 CHF patients, iron deficiency was encountered in 57% of patients with anaemia but also in 32% of those without anaemia (37% overall prevalence), while it was independently associated with reduced event-free survival at 36 months.6 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Therapy with i.v. iron in patients with chronic heart failure (CHF) and iron deficiency (ID) improves symptoms, functional capacity, and quality of life. We sought to investigate whether these beneficial outcomes are independent of anaemia. FAIR-HF randomized 459 patients with CHF [NYHA class II or III, LVEF ≤40% (NYHA II) or ≤45% (NYHA III)] and ID to i.v. iron as ferric carboxymaltose (FCM) or placebo in a 2:1 ratio. We analysed the efficacy and safety according to the presence or absence of anaemia (haemoglobin ≤120 g/L) at baseline. Of 459 patients, 232 had anaemia at baseline (51%). The effect of FCM on the primary endpoints of self-reported Patient Global Assessment (PGA) and NYHA class at week 24 was similar in patients with and without anaemia [odds ratio (OR) for improvement, 2.48 vs. 2.60, P = 0.97 for PGA and 1.90 vs. 3.39, P = 0.51 for NYHA). Results were also similar for the secondary endpoints, including PGA and NYHA at weeks 4 and 12, 6 min walk test distance, Kansas City Cardiomyopathy Questionnaire overall score, and European Quality of Life-5 Dimensions Visual Analogue Scale at most time points. Regarding safety, no differences were noticed in the rates of death or first hospitalization between FCM and placebo both in anaemic and in non-anaemic patients. Treatment of ID with FCM in patients with CHF is equally efficacious and shows a similar favourable safety profile irrespective of anaemia. Iron status should be assessed in symptomatic CHF patients both with and without anaemia and treatment of ID should be considered.
    European Journal of Heart Failure 06/2013; 15(11). DOI:10.1093/eurjhf/hft099 · 6.53 Impact Factor
  • Source
    • "Renal dysfunction is highly prevalent in patients with advanced heart failure [11]. Roughly half of patients with systolic heart failure have a GFR less than 60 mL/min [12]. The mechanisms underlying renal dysfunction in heart failure are mainly hemodynamic. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Cardiorenal syndrome has been recently divided into 5 categories, according to acute or chronic evolution and primary organ dysfunction. Anemia can also accompany this disorder, leading to a more complex situation. This study aims to analyze the renal outcomes of patients, specifically patients with chronic Cardiorenal syndrome, with or without anemia, long-term after heart transplantation. Material/Methods This was a retrospective cohort study on chronic Cardiorenal syndrome patients submitted to heart transplantation. Patients were divided according to presence of anemia and renal dysfunction before heart transplantation. Results A total of 108 patients (92 males) with the mean age of 45±12 years were included. The etiologies of the heart failure were hypertensive dilated myocardiopathy (66%), ischemic (14%) and Chagasic (12%). Before the heart transplantation, 51 patients had an eGFR less than 60 mL/min. From these, 24 had concomitant anemia. One year after the transplantation, patients with previous isolated renal dysfunction ameliorates eGFR (45±11 vs. 65±26 mL/min, p<0.001), while those patients with previous renal dysfunction and anemia presented no improvement (eGFR 44±14 vs. 47±13 mL/min, p=0.619) 1 year after heart transplantation. Moreover, higher hemoglobin was an independent predictor of eGFR improvement after heart transplantation when associated with previous renal dysfunction (OR 1.8; CI 1.2–3.6, p<0.01 for each hemoglobin increment of 1 g/dL). Conclusions Patients with isolated Cardiorenal syndrome presented partial renal function recovery after heart transplantation, while the presence of cardiorenal anemia was a marker of renal function non-recovery 1 year after heart transplantation.
    Medical science monitor: international medical journal of experimental and clinical research 10/2012; 18(10):CR611-616. DOI:10.12659/MSM.883487 · 1.43 Impact Factor
Show more